Cargando…

Viral hepatitis: Milestones, unresolved issues, and future goals

In this review the current overall knowledge on hepatitis A, B, C, D, and E will be discussed. These diseases are all characterized by liver inflammation but have significant differences in distribution, transmission routes, and outcomes. Hepatitis B virus and hepatitis C virus are transmitted by ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Torre, Pietro, Aglitti, Andrea, Masarone, Mario, Persico, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326259/
https://www.ncbi.nlm.nih.gov/pubmed/34366625
http://dx.doi.org/10.3748/wjg.v27.i28.4603
_version_ 1783731749521457152
author Torre, Pietro
Aglitti, Andrea
Masarone, Mario
Persico, Marcello
author_facet Torre, Pietro
Aglitti, Andrea
Masarone, Mario
Persico, Marcello
author_sort Torre, Pietro
collection PubMed
description In this review the current overall knowledge on hepatitis A, B, C, D, and E will be discussed. These diseases are all characterized by liver inflammation but have significant differences in distribution, transmission routes, and outcomes. Hepatitis B virus and hepatitis C virus are transmitted by exposure to infected blood, and in addition to acute infection, they can cause chronic hepatitis, which in turn can evolve into cirrhosis. It is estimated that more than 300 million people suffer from chronic hepatitis B or C worldwide. Hepatitis D virus, which is also transmitted by blood, only affects hepatitis B virus infected people, and this dual infection results in worse liver-related outcomes. Hepatitis A and E spread via the fecal–oral route, which corresponds mainly to the ingestion of food or water contaminated with infected stools. However, in developed countries hepatitis E is predominantly a zoonosis. Although hepatitis A virus and hepatitis E virus are usually responsible for a self-limiting hepatitis, a serious, rarely fatal illness is also possible, and in immunosuppressed patients, such as organ transplant recipients, hepatitis E virus infection can become chronic. The description of goals achieved, unresolved issues, and the latest research on this topic may make it possible to speculate on future scenarios in the world of viral hepatitis.
format Online
Article
Text
id pubmed-8326259
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-83262592021-08-06 Viral hepatitis: Milestones, unresolved issues, and future goals Torre, Pietro Aglitti, Andrea Masarone, Mario Persico, Marcello World J Gastroenterol Review In this review the current overall knowledge on hepatitis A, B, C, D, and E will be discussed. These diseases are all characterized by liver inflammation but have significant differences in distribution, transmission routes, and outcomes. Hepatitis B virus and hepatitis C virus are transmitted by exposure to infected blood, and in addition to acute infection, they can cause chronic hepatitis, which in turn can evolve into cirrhosis. It is estimated that more than 300 million people suffer from chronic hepatitis B or C worldwide. Hepatitis D virus, which is also transmitted by blood, only affects hepatitis B virus infected people, and this dual infection results in worse liver-related outcomes. Hepatitis A and E spread via the fecal–oral route, which corresponds mainly to the ingestion of food or water contaminated with infected stools. However, in developed countries hepatitis E is predominantly a zoonosis. Although hepatitis A virus and hepatitis E virus are usually responsible for a self-limiting hepatitis, a serious, rarely fatal illness is also possible, and in immunosuppressed patients, such as organ transplant recipients, hepatitis E virus infection can become chronic. The description of goals achieved, unresolved issues, and the latest research on this topic may make it possible to speculate on future scenarios in the world of viral hepatitis. Baishideng Publishing Group Inc 2021-07-28 2021-07-28 /pmc/articles/PMC8326259/ /pubmed/34366625 http://dx.doi.org/10.3748/wjg.v27.i28.4603 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Torre, Pietro
Aglitti, Andrea
Masarone, Mario
Persico, Marcello
Viral hepatitis: Milestones, unresolved issues, and future goals
title Viral hepatitis: Milestones, unresolved issues, and future goals
title_full Viral hepatitis: Milestones, unresolved issues, and future goals
title_fullStr Viral hepatitis: Milestones, unresolved issues, and future goals
title_full_unstemmed Viral hepatitis: Milestones, unresolved issues, and future goals
title_short Viral hepatitis: Milestones, unresolved issues, and future goals
title_sort viral hepatitis: milestones, unresolved issues, and future goals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326259/
https://www.ncbi.nlm.nih.gov/pubmed/34366625
http://dx.doi.org/10.3748/wjg.v27.i28.4603
work_keys_str_mv AT torrepietro viralhepatitismilestonesunresolvedissuesandfuturegoals
AT aglittiandrea viralhepatitismilestonesunresolvedissuesandfuturegoals
AT masaronemario viralhepatitismilestonesunresolvedissuesandfuturegoals
AT persicomarcello viralhepatitismilestonesunresolvedissuesandfuturegoals